stoxline Quote Chart Rank Option Currency Glossary
  
Mustang Bio, Inc. (MBIO)
2.9  -0.03 (-1.02%)    02-11 19:59
Open: 2.9
High: 3.04
Volume: 54,339
  
Pre. Close: 2.93
Low: 2.765
Market Cap: 4(M)
Technical analysis
2025-02-11 4:47:29 PM
Short term     
Mid term     
Targets 6-month :  10.76 1-year :  15.53
Resists First :  9.21 Second :  13.3
Pivot price 3.74
Supports First :  2.6 Second :  2.16
MAs MA(5) :  2.86 MA(20) :  4.11
MA(100) :  9.64 MA(250) :  19.86
MACD MACD :  -1.5 Signal :  -1.5
%K %D K(14,3) :  5.6 D(3) :  3.8
RSI RSI(14): 29
52-week High :  74.5 Low :  2.6
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MBIO ] has closed above bottom band by 22.4%. Bollinger Bands are 34.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.04 - 3.06 3.06 - 3.08
Low: 2.73 - 2.75 2.75 - 2.76
Close: 2.87 - 2.9 2.9 - 2.93
Company Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Headline News

Tue, 11 Feb 2025
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire

Mon, 10 Feb 2025
Mustang Bio Announces Closing of $8 Million Public Offering - The Manila Times

Mon, 10 Feb 2025
Mustang Bio (MBIO) Secures Critical $8M Financing Through Strategic Share Offering - StockTitan

Thu, 06 Feb 2025
Capital Raise Alert: Mustang Bio Secures Fresh $8M Funding Through Strategic Share & Warrant Offering - StockTitan

Wed, 22 Jan 2025
Mustang Bio stock plunges to 52-week low of $4 - MSN

Tue, 14 Jan 2025
Mustang Bio Lauds New Stock Split - Baystreet.ca

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1 (M)
Shares Float 43 (M)
Held by Insiders 11.8 (%)
Held by Institutions 4.3 (%)
Shares Short 37 (K)
Shares Short P.Month 7 (K)
Stock Financials
EPS -66.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.94
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -96.6 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -15.8
Qtrly Earnings Growth 0 %
Operating Cash Flow -17 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -0.05
PEG Ratio 0
Price to Book value -3.09
Price to Sales 0
Price to Cash Flow -0.23
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android